Rep. Maria Elvira Purchases Biogen Inc. Shares
Maria Elvira disclosed buying Biogen Inc. shares valued between $1,001 and $15,000.
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Maria Elvira (R)
- Status:
- Member — House
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jun 9, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Biogen Inc. ($BIIB) | Buy | May 11, 2026 | $50,001 - $100,000 |
Key Points
- Maria Elvira, a member of the House, bought Biogen shares valued between $1,001 and $15,000 on May 11, 2026.
- Biogen Inc. trades near $199.96 with a market cap of approximately $29.5 billion and a P/E ratio of 21.5.
- Analysts from Needham and RBC Capital have recently given Biogen a 'buy' rating with price targets of $255 and $227 respectively.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Maria Elvira, a member of the U.S. House of Representatives, recently disclosed a purchase of Biogen Inc. shares valued between $1,001 and $15,000. The transaction was reported on June 9, 2026, but took place on May 11, 2026. Biogen, trading on the NasdaqGS under the ticker BIIB, is a major player in the healthcare sector.
Maria Elvira vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Biogen Inc. Stock Down 9.1%
Shares of NasdaqGS:BIIB are currently trading near $199.96. Biogen Inc. has a market capitalization of approximately $29.5 billion. The company maintains a price-to-earnings (P/E) ratio of 21.5 and a forward P/E ratio of 12.0. It has a beta of 0.177, indicating lower volatility compared to the market. The stock's 52-week range spans from $121.05 to $205.97, with a 50-day moving average of $188.47 and a 200-day moving average of $173.14.
$BIIB stock price
Daily closing prices, year to date. Not investment advice.
Other Institutional Activity in Biogen Inc.
Institutional investors have been actively trading Biogen shares. BlackRock, Inc. increased its holdings by 1,163,231 shares, ending with 15,974,601 shares valued at about $2.93 billion. FMR LLC significantly boosted its position by 3,381,678 shares, holding a total of 12,807,541 shares worth approximately $2.35 billion. Meanwhile, State Street Corp made a minor addition of 8,902 shares, bringing its total to 7,167,922 shares valued at $1.31 billion.
Recent Earnings
Biogen reported revenue of $9.94 billion, reflecting a growth of 1.9%. The company's net margin stands at 13.8%, and it has a return on equity (ROE) of 7.7%. Biogen is expected to announce its next earnings results on April 29, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
5 target raises vs 1 cuts.
-
EPS & revenue
EPS beat estimates by 26.3%. Revenue beat estimates by 7.7%.
-
Profit surprise
EBITDA missed by 7 percent. Operating income missed by 14 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
5 target raises, 1 target cut.
-
Earnings quality
Gross margin down 2.9 points. Operating margin down 14.1 points. Positive free cash flow.
Earnings Call Summary
Biogen had a very strong first quarter with growth products generating 851 million dollars, up 12 percent year-over-year. LEQEMBI sales surged 74 percent to 168 million dollars, benefiting from expansion in the U.S., Japan, and China. The company highlighted real-world evidence showing nearly 80 percent of LEQEMBI patients remain on therapy at 18 months, supporting the durability of treatment. High-dose SPINRAZA launched successfully with 20 percent of U.S. patients already switching, and the company is preparing for multiple pipeline readouts starting this year, including data on tau-targeting drug BIIB080 and lupus candidate Litifilimab.
Guidance Biogen reaffirmed its full-year guidance, confident in underlying business strength. The company expects to close the Apellis acquisition in the second quarter and will provide combined guidance after close. Management noted about 600 million dollars of contract manufacturing revenue expected this year, roughly two-thirds in the first half. They anticipate the acquisition will be accretive to earnings per share in 2027.
Slightly positive report. The quarter was acceptable, but the forward setup is not strong.
Insider Buying and Selling at Biogen Inc.
Several insiders have been buying shares of Biogen. On June 9, 2026, Menelas Pangalos purchased 2,370 shares, while Eric Rowinsky and Stephen Sherwin each acquired 1,505 shares. Maria Freire bought 2,005 shares on the same day. These transactions were not part of a pre-arranged trading plan.
Analysts Set New Price Targets
On June 8, 2026, Needham upgraded Biogen to a 'buy' rating, setting a price target of $255. RBC Capital maintained its 'buy' rating with a target of $227 on May 27, 2026. Piper Sandler reiterated a 'buy' rating with a $225 target on May 15, 2026. The consensus among 30 analysts is a 'buy' with an average target price of $220.63.
About Biogen Inc.
Biogen Inc., headquartered in Cambridge, Massachusetts, is a leading biotechnology company. It focuses on discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is known for its treatments for multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease, among others. Biogen operates globally, with a workforce of approximately 7,500 employees.
Bottom Line
Maria Elvira's purchase of Biogen shares highlights ongoing interest in this major biotech firm. As a leader in neurological therapies, Biogen continues to attract attention from both institutional investors and analysts. While this disclosure is based on past transactions, it provides insight into the company's appeal in the market.
Get Biogen Inc. alerts
New 13F filings, insider trades, and analyst moves on $BIIB, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.